MINNEAPOLIS – October 17, 2012 – Medtronic, Inc.’s (NYSE: MDT) Melody® Transcatheter Pulmonary Valve was awarded the Prix Galien USA 2012 for Best Medical Technology last night. The Prix Galien Award, considered the biomedical industry’s highest accolade and widely recognized as the industry’s equivalent of the Nobel Prize in medicine, recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices.
Stentys has announced that one-year interim results from the APPOSITION III study will be presented during the Transcatheter Cardiovascular Therapeutics (TCT) conference (Miami, USA, 22–26 October).
MiCardia has announced that a scientific presentation and a live procedure with the enCorSQ Mitral Valve Repair System were presented at the 2nd Mitral Days Heart Surgery Symposium in Stuttgart, Germany to 200 cardiac surgeons and other professionals.
On 1 October 2012,Biosensors International Group and Terumo Corporation announced an extension of their existing licensing agreements, under which Terumo may continue to incorporate BioMatrix technology in the production, marketing and selling of Terumo’s drug‐eluting stent systems in markets worldwide, outside of the United States.
Svelte Medical Systems announced on 10 October 2012 the appointment of Jack Darby to the position of president and chief executive officer. Mark Pomeranz will continue to play a key leadership role at Svelte, serving as chief operating officer.
Edwards Lifesciences has announced that it has completed the acquisition of BMEYE, a privately held Dutch company that specialises in the development of non-invasive technology for advanced haemodynamic monitoring. BMEYE’s technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.
Cardionovum announced on 9 October 2012 that it has established its distribution network in 57 countries outside the United States since the beginning of the year.
On 10 October 2012, Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease.
Un equipo de investigadores del Vall d Hebron Institut de Recerca (VHIR) ha presentado los resultados de un amplio estudio epidemiológico, para evaluar el riesgo de la suspensión de tratamientos antiagregantes, durante el primer año, después de la colocación de un stent liberador de fármacos o farmacoactivo. Los resultados del estudio han sido publicados hoy en la revista JACC (Journal of American College of Cardiology) y han merecido una editorial en la misma revista. El estudio indica que la suspensión de estos tratamientos, durante el primer año después de la colocación del stent, no parece aumentar el riesgo de aparición de problemas cardíacos mayores, siempre que la interrupción sea temporal, durante un período corto de unos 7 días de duración, de manera controlada y pasado el primer mes desde la implantación del stent
St Jude Medical has announced the launch of its MediGuide Technology. According to a company release, this is the first and only three-dimensional (3-D) navigation system intended for the evaluation of vascular and cardiac anatomy on a recorded fluoroscopic image instead of live fluoroscopy (a series of X-ray images). The use of recorded images allows physicians to reduce the duration of radiation exposure during cardiovascular procedures, revolutionising medical imaging procedures in the electrophysiology (EP) lab.
On 5 October, the UK’s National Institute of Health and Clinical Excellence (NICE) launched a consultation on its draft quality standard for the management of patients with hypertension.
According to a study published in the European Journal of Heart Failure, severe aortic stenosis patients with low-mean gradient and reduced left ventricular ejection fraction (LVEF) have worse outcomes after transcatheter aortic valve implantation (TAVI) than patients with preserved LVEF and high-mean gradient.
VIDEO
SAN DIEGO, Oct. 4, 2012 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has received clearance to market its new Visions® PV .035 Digital IVUS Catheter in both the US and Europe. The new intravascular ultrasound catheter is designed to image large vessels and facilitate the use of less iodinated contrast in endovascular procedures.
For decades, surgical aortic valve replacement has been the standard of care for patients with symptomatic aortic stenosis, but in the last 10 years, transcatheter aortic valve implantation (TAVI) has emerged as a new treatment option. More than 50,000 valves have been implanted and in the PARTNER trial, TAVI has been shown to reduce two-year mortality by 25% as compared to medical treatment in patients not eligible for surgery. Moreover, it is non-inferior to surgery in terms of two-year survival for patients at high surgical risk.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos